Quantum Biopharma (NASDAQ:QNTM) Rating Lowered to “Strong Sell” at Wall Street Zen

Quantum Biopharma (NASDAQ:QNTM) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.

Separately, Weiss Ratings cut shares of Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Quantum Biopharma Price Performance

NASDAQ:QNTM opened at $3.24 on Friday. Quantum Biopharma has a fifty-two week low of $2.07 and a fifty-two week high of $31.91. The stock’s 50-day moving average is $4.77 and its two-hundred day moving average is $4.61. The stock has a market cap of $20.74 million, a PE ratio of -0.39 and a beta of 0.43.

Institutional Trading of Quantum Biopharma

A number of institutional investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in Quantum Biopharma in the fourth quarter valued at about $76,000. Jane Street Group LLC acquired a new position in Quantum Biopharma in the 4th quarter worth about $80,000. Finally, Platform Technology Partners purchased a new stake in shares of Quantum Biopharma during the 1st quarter worth about $199,000. Institutional investors and hedge funds own 1.24% of the company’s stock.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.